Activation of CB1 and CB2 via different immunologic and tumor-intrinsic pathways has led to tumor promotion in colorectal carcinoma (11, 12), hepatocellular carcinoma (13), glioblastoma, lung carcinoma (14), esophageal cancer (15), prostate cancer (16) pancreatic cancer (17) ovarian cancer (18), breast cancer (19) and others (20–23). Here, CNR2 is linked to neoplasm.